Latigo is a clinical-stage company developing non-opioid pain medications that target pain at its source, aiming to provide effective and rapid relief without the risk of addiction. The company addresses the significant unmet need for new pain therapies, as current treatments often lead to dependency and have remained unchanged for decades.
Funding
$154M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WVFounders
Product
Problem
Current pain management treatments often rely on opioids, which carry a high risk of addiction and significant side effects. The standard of care for pain relief has remained largely unchanged for decades, leaving a substantial unmet need for safer and more effective alternatives.
Solution
Latigo Biotherapeutics is developing a new class of non-opioid pain medications designed to target pain at its source. Their approach aims to provide rapid and effective pain relief without the risk of dependency associated with traditional opioid treatments. By focusing on innovative mechanisms, Latigo seeks to offer a best-in-class profile for pain management, reducing stress and facilitating healing.
Target Audience
Latigo's primary target audience includes patients suffering from acute or chronic pain who are seeking non-addictive alternatives to traditional opioid-based pain management.
Features
- Development of non-opioid pain medications
- Focus on targeting the source of pain
- Designed for rapid-acting pain relief
- Aims to avoid the risk of addiction associated with opioids